

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0300

TITLE: Structural Basis for BRCA1 Function in Breast Cancer

PRINCIPAL INVESTIGATOR: John A. Ladias, M.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center  
Boston, Massachusetts 02215

REPORT DATE: April 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**BEST AVAILABLE COPY**

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> April 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Apr 2003 - 31 Mar 2004)	
<b>4. TITLE AND SUBTITLE</b> Structural Basis for BRCA1 Function in Breast Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0300	
<b>6. AUTHOR(S)</b> John A. Ladias, M.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Beth Israel Deaconess Medical Center Boston, Massachusetts 02215  E-Mail: jladias@bidmc.harvard.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				
<b>11. SUPPLEMENTARY NOTES</b> Original contains color plates: All DTIC reproductions will be in black and white.				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b> The Breast Cancer Susceptibility gene 1 (BRCA1) encodes an 1863-amino acid protein that plays a central role in the pathogenesis of hereditary breast cancer. The BRCA1 protein contains an N-terminal RING finger and two C-terminal BRCT domains (BRCT1 and BRCT2), which are critical for BRCA1-mediated tumor suppression and are targets for cancer-causing mutations. The BRCA1 RING interacts with the RING domain of BARD1, another protein involved in breast cancer pathogenesis, and with the C-terminal domain of BAP1 (amino acids 598-729), a ubiquitin hydrolase that enhances BRCA1-mediated cell growth suppression, whereas the BRCA1 BRCT domains interact with the C-terminal region of BACH1 (amino acids 888-1063), a helicase-like protein that contributes to the BRCA1 DNA repair function. The present project focuses on the elucidation of the structural basis of the BRCA1 RING and BRCT domain interaction with the proteins BARD1, BAP1, and BACH1 using X-ray crystallography. In the second year of the award we completed the Tasks 2a, 2b, and 2c of the Statement of Work. For the remaining year of the award, we propose to determine the crystal structures of the BRCA1(residues 1-103)/BAP1(residues 598-729), BRCA1(residues 1-304)/BARD1(residues 25-189), and BRCA1(1650-1863)-BACH1(984-995) phosphopeptide complexes.				
<b>14. SUBJECT TERMS</b> Tumor suppressor gene, hereditary breast cancer, DNA repair, structural chemistry, X-ray crystallography			<b>15. NUMBER OF PAGES</b> 9	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

20041028 131

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-7
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7-8
References.....	8-9
Appendices.....	n/a

## **INTRODUCTION**

The Breast Cancer Susceptibility gene 1 (BRCA1) encodes an 1863-amino acid protein that plays a central role in the pathogenesis of hereditary breast cancer (1-3). The BRCA1 protein contains an N-terminal RING finger and two C-terminal BRCT domains (BRCT1 and BRCT2), which are critical for BRCA1-mediated tumor suppression and are targets for cancer-causing mutations (1-4). The BRCA1 RING interacts with the RING domain of BARD1, another protein involved in breast cancer pathogenesis, and with the C-terminal domain of BAP1 (amino acids 598-729), a ubiquitin hydrolase that enhances BRCA1-mediated cell growth suppression, whereas the BRCA1 BRCT domains interact with the C-terminal region of BACH1 (amino acids 888-1063), a helicase-like protein that contributes to the BRCA1 DNA repair function (4-7). Importantly, it has been shown recently that the BRCA1 BRCT domains interact with phosphoserine- or phosphothreonine-containing peptides, including the BACH1 peptide ISRTST(pS)PTFNK, where pS denotes phosphorylated Ser990 (8-10). Moreover, a heterodimer consisting of the RING-encompassing regions of BRCA1 (amino acids 1-304) and BARD1 (amino acids 25-189) functions as a ubiquitin ligase targeting cellular proteins for destruction, whereas the individual BRCA1 and BARD1 domains have very low ubiquitin ligase activities (5). This project focuses on the elucidation of the structural basis of the BRCA1 RING and BRCT domains interaction with BARD1, BAP1, and BACH1, using X-ray crystallography. Because BRCA1 plays a central role in breast cancer pathogenesis, the determination of its three-dimensional structure will facilitate the unraveling of the molecular mechanisms of its function in breast carcinogenesis. The Specific Aims of this proposal are:

**Specific Aim 1.** To co-crystallize and determine the crystal structure of the BRCA1 RING (amino acids 1-103) bound to the C-terminal domain of BAP1 (amino acids 598-729).


**Specific Aim 2.** To determine the crystal structure of the ubiquitin ligase heterodimer consisting of the BRCA1 region spanning amino acids 1-304 and the BARD1 region spanning residues 25-189.

**Specific Aim 3.** To co-crystallize and determine the crystal structure of the BRCA1 BRCT1/BRCT2-containing region (amino acids 1650-1863) complexed with the C-terminal region of BACH1 (amino acids 888-1063).

## **BODY**

During the second year of the award we proceeded with the completion of the experiments proposed in Task 2 of the revised Statement of Work (as described in the first year's progress report). A description of our progress in these studies follows below.

**Task 2a. To clone the BRCA1 BRCT1/BRCT2-containing region (residues 1650-1863), the BAP1 C-terminal domain (residues 598-729), and the BACH1 region (residues 888-1063) into prokaryotic expression vectors for production in *E. coli* cells (months 13-16).** The DNA fragment encoding the human BRCA1 BRCT1/BRCT2 domain (amino acids 1650-1863) was amplified with the polymerase chain reaction (PCR) using the human BRCA1 cDNA as a template and cloned into a modified pTYB12 prokaryotic vector (New England BioLabs), following standard protocols (11). The resulting construct was verified by DNA sequencing and was used to transform *E. coli* ER2566 cells (NEB).



**Figure 1.** (A) Expression of the BRCA1 BRCT1/BRCT2 domain (amino acids 1650-1863) and the BAP1 C-terminal domain (amino acids 598-729). SDS-PAGE of intein-BRCT1/BRCT2 and intein-BAP1 fusion proteins produced in *E. coli* cells. Lane M: protein markers; lanes 1 and 2: uninduced and induced whole-cell extracts, respectively, of *E. coli* ER2566 cells expressing intein-BRCT1/BRCT2 protein; lanes 3 and 4: uninduced and induced whole-cell extracts, respectively, of *E. coli* cells expressing intein-BAP1(598-729) protein. (B) Purified BRCT1/BRCT2(1650-1863) protein following overnight cleavage from intein with DTT at 4°C and concentration. (C) Lane M: protein markers; lanes 1-6: eluted fractions of purified BAP1(598-729) protein following overnight cleavage from intein with DTT at 4°C. (D) Expression of the BACH1 domain (residues 888-1063). SDS-PAGE of intein-BACH1 fusion protein produced in *E. coli* ER2566 cells. Lane M: protein markers; lanes 1 and 2: uninduced and induced whole-cell extracts, respectively, of *E. coli* cells expressing intein-BACH1 protein. (E) Microcrystalline plates of recombinant BRCA1 RING protein (residues 1-103) bound to BAP1 C-terminal domain (amino acids 598-729), grown using the sitting drop vapor diffusion method. (F) Needle-like crystals of the BRCA1 BRCT1/BRCT2 domain (amino acids 1650-1863) bound to the BACH1 phosphoserine-containing peptide ISRTST(pS)PTFNK, grown using the sitting drop vapor diffusion method.

To clone the C-terminal domain of human BAP1 we obtained the cDNA KIAA0272 from Dr. Takahiro Nagase at the Kazusa DNA Research Institute, Japan, which codes for the human BAP1 protein (accession number D87462). Using this cDNA as a template, we amplified by PCR a DNA fragment encoding the BAP1 C-terminal domain (residues 598-729) and cloned it into a modified pTYB12 prokaryotic vector, using standard methods. The resulting construct was verified by DNA sequencing and was used to transform *E. coli* ER2566 cells (NEB).

Several requests to obtain the human BACH1 cDNA from other laboratories were denied, so we proceeded with cloning the DNA fragment coding for the BACH1 region (residues 888-1063) from a human brain cDNA library (Clontech) using PCR. The obtained DNA fragment was cloned into a modified pTYB12 prokaryotic vector. The resulting construct was verified by DNA sequencing and was used to transform *E. coli* ER2566 cells (NEB).

**Task 2b. To express the BRCA1 BRCT1/BRCT2-containing region (residues 1650-1863), the BAP1 C-terminal domain (residues 598-729), and the BACH1 region (residues 888-1063) in *E. coli* cells (months 17-24).** The BRCA1 BRCT1/BRCT2 protein was produced in ER2566 cells as a fusion with intein. Expression of the fusion protein was induced at 20°C by 1 mM IPTG at OD<sub>600</sub> of 0.6 (Figure 1A, lanes 1,2), purified on chitin beads (NEB) using the manufacturer's protocols, was further purified by size-exclusion chromatography and was concentrated using Centriprep concentrators (Amicon) for use in crystallization experiments (Figure 1B), as we described previously (12-17).

For the production of the BAP1(598-729) recombinant protein, we followed a similar approach. Briefly, expression of the BAP1(598-729) protein as a fusion with intein in ER2566 cells was induced at 20°C by 1 mM IPTG at OD<sub>600</sub> of 0.6 (Figure 1A, lanes 3,4), purified on chitin beads (NEB) using the manufacturer's protocols (Figure 1C), was further purified by size-exclusion chromatography and was concentrated using Centriprep concentrators for use in crystallization experiments, as we described previously (12-17).

The recombinant protein BACH1(888-1063) was produced in ER2566 cells as a fusion with intein following a similar strategy. Expression of the fusion protein was induced at 22°C by 1 mM IPTG at OD<sub>600</sub> of 0.6 (Figure 1D, lanes 1,2), purified on chitin beads (NEB) using the manufacturer's protocols, was further purified by gel filtration and was concentrated using Centriprep concentrators for use in crystallization trials, as we described previously (12-17). In general, using this expression system we were able to obtain up to 5-7 mg of recombinant protein (>98% pure as estimated by SDS-PAGE) per liter of bacterial culture.

**Task 2c. To crystallize the BRCA1 BRCT1/BRCT2(1650-1863) in complex with BACH1(888-1063) and the BRCA1(1-103) in complex with BAP1(598-729), using sparse matrix vapor diffusion crystallization methods, seeding, limited proteolysis, and mutagenesis to improve crystallization (months 18-24).** Having purified these proteins to near homogeneity, we proceeded with crystallization experiments. The protein complexes BRCA1(1650-1863)-BACH1(888-1063), BRCA1(1-103)-BAP1(598-729), and BRCA1(1650-1863)-BACH1(984-995) phosphopeptide, were formed by mixing the corresponding proteins at stoichiometric ratios, followed by purification of the complexed proteins by gel filtration. Subsequently, the protein complexes were concentrated and used for crystallization experiments, as described in the original application. To date, the protein complex BRCA1(1650-1863)-BACH1(888-1063) did not yield any crystals. By contrast, small crystals were obtained with the BRCA1(1-103)-BAP1(598-729) complex (Figure 1E), and the BRCA1(1650-1863)-

BACH1(984-995) phosphopeptide complex (Figure 1F). Currently we are in the process of optimizing the crystallization conditions in order to obtain large single crystals of these complexes that diffract to high resolution and determine the structures of these proteins.

### **KEY RESEARCH ACCOMPLISHMENTS**

1. Cloning of the BRCA1 BRCT1/BRCT2-containing region (residues 1650-1863) into a modified pTYB12 prokaryotic expression vector for production in *E. coli* cells (*Task 2a*).
2. Cloning of the BAP1 C-terminal domain (residues 598-729) into a modified pTYB12 prokaryotic expression vector for production in *E. coli* cells (*Task 2a*).
3. Cloning of the BACH1 region (residues 888-1063) into a modified pTYB12 prokaryotic expression vector for production in *E. coli* cells (*Task 2a*).
4. Expression of the BRCA1 BRCT1/BRCT2 (residues 1650-1863) in *E. coli* ER2566 cells and purification of the recombinant protein using chromatographic methods (*Task 2b*).
5. Expression of the BAP1 C-terminal domain (residues 598-729) in *E. coli* ER2566 cells and purification of the recombinant protein using chromatographic methods (*Task 2b*).
6. Expression of the BACH1 region (residues 888-1063) in *E. coli* ER2566 cells and purification of the recombinant protein using chromatographic methods (*Task 2b*).
7. Crystallization experiments of the BRCA1 BRCT1/BRCT2(1650-1863) protein bound to BACH1(888-1063) protein using sparse matrix vapor diffusion crystallization methods, so far producing no crystals (*Task 2c*).
8. Crystallization experiments of the BRCA1 BRCT1/BRCT2(1650-1863) protein bound to the BACH1(985-995) phosphopeptide ISRST(pS)PTFNK using sparse matrix vapor diffusion crystallization methods, resulting in small crystalline plates (*Task 2c*).
9. Crystallization experiments of the BRCA1 RING(1-103) protein bound to BAP1 C-terminal domain (residues 598-729) using sparse matrix vapor diffusion crystallization methods, resulting in small needle-like crystals (*Task 2c*).

### **REPORTABLE OUTCOMES**

The experiments of the second year are still in progress and no new publications have resulted so far.

### **CONCLUSIONS**

In the second year of the award we completed the Tasks 2a, 2b, and 2c of the revised Statement of Work. In addition, the recent discovery that the BRCA1 BRCT1/BRCT2 domains interact with phosphoserine- or phosphothreonine-containing peptides, including the BACH1 peptide ISRTST(pS)PTFNK (8-10), provided a compelling reason for us to initiate crystallization experiments of these domains complexed with this peptide, a task that was not included in the original Statement of Work. The crystal structure of BRCA1 BRCT1/BRCT2 domains bound to the target phosphopeptides will provide much more information than the structures of these domains in the unbound form (18). The information obtained from these

experiments will elucidate the mechanisms underlying regulation of BRCA1 by BAP1 and BACH1 and will reveal the molecular changes induced by cancer-causing mutations in the BRCA1 domains that affect their interaction with BAP1 and BACH1.

## **REFERENCES**

1. Venkitaraman AR. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* **108**: 171-182
2. Scully R, Livingston DM. (2000). In search of the tumour-suppressor functions of BRCA1 and BRCA2. *Nature* **408**: 429-432
3. Welch PL, Owens KN, King MC. (2000). Insights into the functions of BRCA1 and BRCA2. *Trends Genet.* **16**: 69-74
4. Deng CX, Brodie SG. (2000). Roles of BRCA1 and its interacting proteins. *Bioessays* **22**: 728-737
5. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. (2001). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. *J. Biol. Chem.* **276**: 14537-14540
6. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ. (1998). BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene* **16**: 1097-1112
7. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. (2001). BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. *Cell* **105**: 149-160
8. Yu X, Chini CC, He M, Mer G, Chen J. (2003). The BRCT domain is a phospho-protein binding domain. *Science* **302**: 639-642
9. Manke IA, Lowery DM, Nguyen A, Yaffe MB. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. *Science* **302**: 636-639
10. Rodriguez M, Yu X, Chen J, Songyang Z. (2003). Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. *J. Biol. Chem.* **278**: 52914-52918
11. Sambrook J, Fritsch EF, Maniatis T. (1989). *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press)
12. Hiremath CN, Ldias JAA. (1998). Expression and purification of recombinant hRPABC25, hRPABC17, and hRPABC14.4, three essential subunits of human RNA polymerases I, II, and III. *Prot. Expr. Purif.* **13**: 198-294
13. Webster G, Leung T, Karthikeyan S, Birrane G, Ldias JAA. (2001). Crystallographic characterization of the PDZ1 domain of the Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor. *Acta Crystallogr.* **D57**: 714-716
14. Karthikeyan S, Leung T, Birrane G, Webster G, Ldias JAA. (2001). Crystal structure of the PDZ1 domain of the human Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor provides insights into the mechanism of carboxyl-terminal leucine recognition by class I PDZ domains. *J. Mol. Biol.* **308**: 963-973



15. Karthikeyan S, Leung T, Ladas JAA. (2001). Structural basis of the Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* **276**: 19683-19686
16. Karthikeyan S, Leung T, Ladas JAA. (2002). Structural Determinants of the Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor interaction with the  $\beta_2$  adrenergic and platelet-derived growth factor receptors. *J. Biol. Chem.* **277**: 18973-18978
17. Birrane G, Chung J, Ladas JAA. (2003). Novel Mode of Ligand Recognition by the Erbin PDZ Domain. *J. Biol. Chem.* **278**: 1399-1402
18. Williams RS, Green R, Glover JN. (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. *Nat. Struct. Biol.* **8**: 838-842